Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared

Biotech Giants: SG&A Spending Trends Unveiled

__timestampRegeneron Pharmaceuticals, Inc.Vericel Corporation
Wednesday, January 1, 201450475500013774000
Thursday, January 1, 201583852600022479000
Friday, January 1, 2016117769700027388000
Sunday, January 1, 2017132043300035610000
Monday, January 1, 2018155620000049007000
Tuesday, January 1, 2019183480000061139000
Wednesday, January 1, 2020134600000068836000
Friday, January 1, 2021182490000097592000
Saturday, January 1, 20222115900000106903000
Sunday, January 1, 20232631300000120998000
Monday, January 1, 20242954400000
Loading chart...

Cracking the code

SG&A Spending Patterns: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial strategies is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Vericel Corporation have showcased distinct approaches to their Selling, General, and Administrative (SG&A) expenses. Regeneron, a giant in the industry, has seen its SG&A expenses grow by over 400% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Vericel, a smaller player, has increased its SG&A spending by approximately 780% during the same period, indicating a robust push to establish its presence. This divergence highlights the varied paths companies take in scaling operations and capturing market share. As of 2023, Regeneron's SG&A expenses are nearly 22 times that of Vericel's, underscoring the scale and scope of its operations. These insights provide a window into the strategic priorities of these biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025